Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950034 | 0.80 | KDM4E (0.45) | NPC1RAB9ASMN1; SMN2KDM4ETAAR1 | |
| SCHEMBL4983838 | 0.80 | KMT2A (0.51) | SMN1; SMN2KDM4ELMNAMEN1KMT2A | |
| SCHEMBL4083916 | 0.79 | BACE1 (0.38) | NPC1RAB9ASMN1; SMN2KDM4ETAAR1 | |
| SCHEMBL13495002 | 0.77 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KDM4ETAAR1 | |
| SCHEMBL3224949 | 0.77 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KDM4ETAAR1 | |
| SCHEMBL7301446 | 0.76 | MME (0.44) | KDM4EMEN1KMT2A | |
| SCHEMBL1900364 | 0.76 | KMT2A (0.54) | RAB9ASMN1; SMN2L3MBTL1LMNAKMT2A | |
| SCHEMBL1520684 | 0.75 | BCAT2 (0.72) | NPC1RAB9ASMN1; SMN2KDM4ETAAR1 | |
| SCHEMBL26906281 | 0.75 | BCAT2 (0.72) | NPC1RAB9ASMN1; SMN2KDM4ETAAR1 | |
| SCHEMBL97054 | 0.74 | KMT2A (0.43) | NPC1KDM4EL3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | NPC1 1740/4885RAB9A 2441/4885SMN1; SMN2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.